Scholarlink

<p>Knee arthroscopy is one of the most frequently performed orthopedic procedures worldwide, with more than 4 million operations conducted annually. A&#xa0;rare but potentially serious complication is deep vein thrombosis (DVT), with reported incidences ranging from 0.14% to 17.9% following arthroscopic procedures. The currently available evidence does not provide a&#xa0;clear recommendation for routine pharmacological thromboprophylaxis after knee arthroscopy. International guidelines remain inconsistent. In Germany, approximately 96% of patients receive low-molecular-weight heparin (LMWH) prophylaxis after arthroscopy, whereas the use of pharmacological prophylaxis is considerably less common in North America. The German S3 guidelines do not recommend routine pharmacological thromboprophylaxis following uncomplicated arthroscopic procedures in patients without additional risk factors or prolonged immobilization; however, in patients at increased risk, pharmacological prophylaxis can be administered until full mobility and weight-bearing capacity have been regained.</p><p>There is currently no general recommendation for routine pharmacological thromboprophylaxis following uncomplicated diagnostic knee arthroscopy in patients without risk factors. Instead, a&#xa0;risk-adapted approach is recommended. In patients with relevant risk factors LMWH or factor&#xa0;Xa inhibitors are considered appropriate prophylactic options. Regardless of the pharmacological treatment, early mobilization on the day of surgery plays a&#xa0;central role in thrombosis prevention. Current clinical practice is often guided by local institutional protocols, as high-quality evidence-based guidelines are still lacking.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Perioperative Thromboseprophylaxe bei Arthroskopie des Kniegelenks

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年7月27日

查看全文
  • Johannes Neugebauer

摘要

Knee arthroscopy is one of the most frequently performed orthopedic procedures worldwide, with more than 4 million operations conducted annually. A rare but potentially serious complication is deep vein thrombosis (DVT), with reported incidences ranging from 0.14% to 17.9% following arthroscopic procedures. The currently available evidence does not provide a clear recommendation for routine pharmacological thromboprophylaxis after knee arthroscopy. International guidelines remain inconsistent. In Germany, approximately 96% of patients receive low-molecular-weight heparin (LMWH) prophylaxis after arthroscopy, whereas the use of pharmacological prophylaxis is considerably less common in North America. The German S3 guidelines do not recommend routine pharmacological thromboprophylaxis following uncomplicated arthroscopic procedures in patients without additional risk factors or prolonged immobilization; however, in patients at increased risk, pharmacological prophylaxis can be administered until full mobility and weight-bearing capacity have been regained.

There is currently no general recommendation for routine pharmacological thromboprophylaxis following uncomplicated diagnostic knee arthroscopy in patients without risk factors. Instead, a risk-adapted approach is recommended. In patients with relevant risk factors LMWH or factor Xa inhibitors are considered appropriate prophylactic options. Regardless of the pharmacological treatment, early mobilization on the day of surgery plays a central role in thrombosis prevention. Current clinical practice is often guided by local institutional protocols, as high-quality evidence-based guidelines are still lacking.